Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% ...

Immunovant, Inc.’s IMVT share price has dipped by 11.06%, which has investors questioning if this is right time to buy.

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Learn more about whether Alvotech or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which ...

while Roivant (NASDAQ:ROIV) experienced a 2% decline in today’s trading session. The dip came unexpectedly following the announcement of positive results from their respective studies on batoclimab ...

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus to its lead asset, IMVT-1402.

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab in myasthenia gravis (MG) and initial results from Period 1 of its Phase ...

Immunovant (NASDAQ:IMVT) traded lower in the premarket on Wednesday after the company announced clinical trial data related to its initial drug candidate, batoclimab, against autoimmune disorders ...